IN2012DN02345A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02345A
IN2012DN02345A IN2345DEN2012A IN2012DN02345A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A IN 2345DEN2012 A IN2345DEN2012 A IN 2345DEN2012A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A
Authority
IN
India
Prior art keywords
nucleic acid
stranded
methods
tlrs
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Bruce A Sullenger
Jaewoo Lee
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of IN2012DN02345A publication Critical patent/IN2012DN02345A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2345DEN2012 2009-09-16 2010-09-16 IN2012DN02345A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24309009P 2009-09-16 2009-09-16
PCT/US2010/002516 WO2011034583A2 (fr) 2009-09-16 2010-09-16 Inhibition de l'activation des récepteurs du type toll endosomaux

Publications (1)

Publication Number Publication Date
IN2012DN02345A true IN2012DN02345A (fr) 2015-08-21

Family

ID=43759220

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2345DEN2012 IN2012DN02345A (fr) 2009-09-16 2010-09-16

Country Status (6)

Country Link
US (3) US9468650B2 (fr)
EP (1) EP2477641B1 (fr)
CN (1) CN102639142A (fr)
CA (1) CA2774460C (fr)
IN (1) IN2012DN02345A (fr)
WO (1) WO2011034583A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2139992A4 (fr) 2007-03-30 2011-08-10 Univ Duke Procede pour moduler l'activite d'une molecule d'acide nucleique
US9468650B2 (en) 2009-09-16 2016-10-18 Duke University Inhibition of endosomal toll-like receptor activation
US9687529B2 (en) 2011-05-05 2017-06-27 Duke University Method of controlling coagulation
WO2014169043A1 (fr) * 2013-04-09 2014-10-16 Duke University Agents anti-inflammatoires et leurs procédés d'utilisation
WO2015161094A1 (fr) 2014-04-16 2015-10-22 Duke University Nanofibres cationiques électrofilées et procédés pour leur fabrication et leur utilisation
CN109982707A (zh) 2016-09-16 2019-07-05 杜克大学 血管性血友病因子（vwf）靶向剂及其使用方法
EP3601592A4 (fr) 2017-03-23 2020-11-25 Duke University Inversion médiée par antidote de coloration d'aptamère extracellulaire
CN111182925A (zh) * 2017-05-30 2020-05-19 纽约市哥伦比亚大学理事会 阳离子核酸清除剂及其用途
WO2021016924A1 (fr) * 2019-07-31 2021-02-04 中山大学 Polymère cationique et particules utilisables pour traiter le psoriasis
EP4249913A1 (fr) * 2022-03-22 2023-09-27 Centre Hospitalier Universitaire de Nîmes Inhibiteur du récepteur de type toll 3 pour la prévention et/ou le traitement de troubles chez des patients ayant des antécédents personnels de thromboembolie veineuse (vte)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919761A (en) 1992-08-14 1999-07-06 The Board Of Regents Of The University Of Michigan Peptides for heparin and low molecular weight heparin anticoagulation reversal
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1343371A4 (fr) 2000-09-08 2004-08-04 Invitrogen Corp Compositions et procedes permettant d'obtenir une sensibilite et une specificite ameliorees de la synthese d'acide nucleique
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
EP1347776A2 (fr) 2001-01-05 2003-10-01 Intercell Biomedizinische Forschungs- und Entwicklungs AG Utilisations de composes polycationiques
PL362699A1 (en) 2001-03-08 2004-11-02 Merck Patent Gmbh Modified protamine with reduced immunogenicity
ES2474192T3 (es) 2001-05-25 2014-07-08 Duke University Moduladores de agentes farmacol�gicos
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
EP1575976A4 (fr) 2001-11-02 2006-08-23 Insert Therapeutics Inc Procedes et compositions permettant l'utilisation therapeutique de l'interference arn
US20030180250A1 (en) 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
CA2501132A1 (fr) 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Materiaux et compositions a base de cyclodextrine, et utilisations correspondantes
WO2006001810A2 (fr) 2003-07-15 2006-01-05 California Institute Of Technology Acides nucleiques inhibiteurs ameliores
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
CN103045601B (zh) 2004-04-22 2015-04-01 雷加多生物科学公司 改良的凝血因子调节物
WO2007001332A2 (fr) * 2004-08-04 2007-01-04 University Of Massachusetts Immunoadhesines anti-pathogene
GB0422877D0 (en) 2004-10-14 2004-11-17 Univ Glasgow Bioactive polymers
DK1866414T3 (da) 2005-03-31 2012-04-23 Calando Pharmaceuticals Inc Inhibitorer af ribonukleotidreduktase-underenhed 2 og anvendelser deraf.
US7611835B2 (en) 2005-09-30 2009-11-03 Battelle Memorial Institute Process for preparing multilayer enzyme coating on a fiber
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
RU2568579C2 (ru) 2006-05-26 2015-11-20 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Введение противосвертывающей системы reg1
EP2275142A3 (fr) * 2006-06-30 2011-05-11 Andre Koltermann Conjugués pour l'immunothérapie du cancer
US20110118187A1 (en) 2006-10-19 2011-05-19 Duke University Reversible platelet inhibition
WO2008063157A2 (fr) 2006-10-25 2008-05-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticoagulant à base de nanoparticules
ES2527412T3 (es) * 2007-02-15 2015-01-23 Mannkind Corporation Método para aumentar la respuesta de los linfocitos T
EP2139992A4 (fr) * 2007-03-30 2011-08-10 Univ Duke Procede pour moduler l'activite d'une molecule d'acide nucleique
CN101808730A (zh) 2007-09-27 2010-08-18 Sca卫生用品公司 粘土连接的聚合物凝胶
WO2009064767A2 (fr) 2007-11-12 2009-05-22 Massachusetts Institute Of Technology Nanofibres bactéricides et procédés d'utilisation
WO2010020008A1 (fr) 2008-08-22 2010-02-25 Polymers Crc Limited Revêtements polymères
US8992991B2 (en) 2009-05-15 2015-03-31 The Johns Hopkins University Multicomponent degradable cationic polymers
US9468650B2 (en) 2009-09-16 2016-10-18 Duke University Inhibition of endosomal toll-like receptor activation
WO2012088059A2 (fr) 2010-12-20 2012-06-28 Virginia Commonwealth University Procédé facile de réticulation et d'incorporation de molécules bioactives dans des échafaudages de fibres électrofilées
US20140234373A1 (en) 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance

Also Published As

Publication number Publication date
US20230248805A1 (en) 2023-08-10
EP2477641A4 (fr) 2013-08-07
US20170095503A1 (en) 2017-04-06
US11617779B2 (en) 2023-04-04
US9468650B2 (en) 2016-10-18
WO2011034583A2 (fr) 2011-03-24
US20120183564A1 (en) 2012-07-19
EP2477641A2 (fr) 2012-07-25
EP2477641B1 (fr) 2024-03-27
WO2011034583A3 (fr) 2011-10-06
CA2774460C (fr) 2016-08-09
CN102639142A (zh) 2012-08-15
CA2774460A1 (fr) 2011-03-24

Similar Documents

Publication Publication Date Title
IN2012DN02345A (fr)
BR112014005205A2 (pt) métodos para etiquetar bibliotecas codificadas com dna
WO2007136736A3 (fr) Procédés de tri et de synthèse d'acides nucléiques
MX2010002113A (es) Metodos para detectar oligonucleotidos.
WO2007127219A3 (fr) Distribution ciblée de leucocytes à l'aide de vecteurs protéiques
HK1116836A1 (en) Multicomponent nucleic acid enzymes and methods for their use
WO2010026488A3 (fr) Procédés et kits de séquençage d'acides nucléiques
BR112014007852A2 (pt) nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos
WO2008063203A3 (fr) Compositions et méthodes de silençage efficace de gènes dans des végétaux
WO2008061537A3 (fr) Oligonucléotides pour moduler l'activité d'arn cible
SG170802A1 (en) Systems and devices for sequence by synthesis analysis
EP2569453A4 (fr) Méthodes d'isolement de l'acide nucléique
WO2005097993A3 (fr) Oligonucleotides d'arn viral immunostimulateurs
WO2008151631A8 (fr) Utilisation de courts oligonucléotides pour des expériences à redondance de réactif dans une analyse fonctionnelle d'arn
EP3358014A3 (fr) Procédé de stabilisation d'acides nucléiques fonctionnels
EP2647711A3 (fr) Voies d'export alternatives pour l'interférence d'ARN exprimée par vecteur
WO2006012468A3 (fr) Detection d'oligonuleotides par hybridation double
MX2007004686A (es) Moleculas de arn de multidominio que comprenden al menos un aptamero para suministrar arn de doble hebra a organismos nocivos.
ATE534737T1 (de) Gezielte abgabe von sirna
AR067135A1 (es) Metodos para aislar arn de fragmento largo de muestras fijas
MXPA02000819A (es) Ligandos de acido nucleico para tenascina-c.
WO2011056073A3 (fr) Composés inédits capables de moduler la néovascularisation et méthodes de traitement faisant appel à ces composés
WO2009012363A3 (fr) Nucléotides et aptamères contenant des groupes acide boronique ayant une liaison sollicitée à des protéines glycosylées et leurs utilisations
WO2020198509A3 (fr) Oligonucléotides modifiés à stabilité accrue
ATE548454T1 (de) Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis